Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 12

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 12
---
holders”), with respect to (i) the adoption of the Agreement and Plan of Merger, dated as of         
 January 10, 2025, by and among Enfusion, Enfusion Ltd. LLC (“Enfusion OpCo”), Clearwater Analytics Holdings, Inc. (“Clearwater”), Poseidon Acquirer, Inc. (“Acquirer”), Poseidon Merger Sub I,                              
 Inc. (“Merger Sub”) and Poseidon Merger Sub II, LLC (“Merger Sub II”), which agreement provides for the acquisition of Enfusion by Clearwater (such agreement, as it may be amended from time to time, the                  
 “Merger Agreement”), a copy of which is included as Annex A to this Proxy Statement/Prospectus, and approval of the Mergers (as defined below), and (ii) the adjournment of the Special Meeting of Enfusion Stockholders to 
 be held on      , 2025 (the “Special Meeting”), if necessary, to solicit additional proxies if there are not sufficient votes to approve the Merger Agreement Proposal (as defined below).                                  |

This document constitutes both a proxy statement of Enfusion and a prospectus of Clearwater. It is a proxy statement because Enfusion is soliciting proxies from its stockholders. It is a prospectus because Clearwater will issue shares of its Class A common stock, par value $0.001 per share (“ Clearwater Common Stock”), in exchange for (i) shares of Enfusion Common Stock, (ii) Enfusion RSUs (as defined below) that are vested as of immediately prior to the Effective Time or that vest in accordance with their terms as a result of the consummation of the Mergers (“ Enfusion Vested RSUs”) and (iii) units of common limited liability company membership interest in Enfusion OpCo (the “ Enfusion Common Units,” and collectively with Enfusion Common Stock and Enfusion Vested RSUs, the “ Eligible Shares,” and holders of Eligible Shares, the “ Enfusion Securityholders”) in the Transactions (as defined below) if the Transactions are completed.

| Q: | What are the Transactions? |

| A: | Enfusion has agreed to be acquired by Clearwater under the terms of the Merger Agreement, which is further                                                                                                                                           
 described in this Proxy Statement/Prospectus. If the Merger Agreement is adopted by Enfusion Stockholders and the other conditions to Closing (as defined below) under the